Related Experiment Video
Updated: Feb 26, 2026

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
Published on: December 7, 2014
Elucidation of the molecular mechanisms underlying adverse reactions associated with a kinase inhibitor using systems
Takahiro Amemiya1, Masashi Honma1,2, Yoshiaki Kariya1
1Department of Pharmacy, The University of Tokyo Hospital, Faculty of Medicine, The University of Tokyo, Tokyo, Japan.
Background/Objectives:
Targeted kinase inhibitors are an important class of agents in anticancer therapeutics, but their limited tolerability hampers their clinical performance. Identification of the molecular mechanisms underlying the development of adverse reactions will be helpful in establishing a rational method for the management of clinically adverse reactions. Here, we selected sunitinib as a model and demonstrated that the molecular mechanisms underlying the adverse reactions associated with kinase inhibitors can efficiently be identified using a systems toxicological approach.
Methods:
First, toxicological target candidates were short-listed by comparing the human kinase occupancy profiles of sunitinib and sorafenib, and the molecular mechanisms underlying adverse reactions were predicted by sequential simulations using publicly available mathematical models. Next, to evaluate the probability of these predictions, a clinical observation study was conducted in six patients treated with sunitinib. Finally, mouse experiments were performed for detailed confirmation of the hypothesized molecular mechanisms and to evaluate the efficacy of a proposed countermeasure against adverse reactions to sunitinib.
Results:
In silico simulations indicated the possibility that sunitinib-mediated off-target inhibition of phosphorylase kinase leads to the generation of oxidative stress in various tissues. Clinical observations of patients and mouse experiments confirmed the validity of this prediction. The simulation further suggested that concomitant use of an antioxidant may prevent sunitinib-mediated adverse reactions, which was confirmed in mouse experiments.
Conclusions:
A systems toxicological approach successfully predicted the molecular mechanisms underlying clinically adverse reactions associated with sunitinib and was used to plan a rational method for the management of these adverse reactions.
Insights
Systems toxicology identified sunitinib
Area of Science:
- Pharmacology
- Toxicology
- Oncology
Background:
- Targeted kinase inhibitors are vital anticancer drugs but often cause adverse reactions.
- Understanding the molecular basis of these side effects is crucial for better patient management.
- Sunitinib serves as a model drug to investigate kinase inhibitor toxicity.
Purpose of the Study:
- To employ a systems toxicological approach to identify mechanisms of sunitinib-induced adverse reactions.
- To predict and validate molecular pathways leading to toxicity.
- To explore potential countermeasures for managing adverse events.
Main Methods:
- Comparative analysis of kinase occupancy profiles for sunitinib and sorafenib.
- In silico simulations using mathematical models to predict toxicological targets.
- Clinical observation in patients and experimental validation in mice.
Main Results:
- In silico analysis predicted that sunitinib inhibits phosphorylase kinase, causing oxidative stress.
- Clinical and animal studies confirmed this prediction.
- Antioxidant co-administration was predicted and experimentally validated to mitigate sunitinib toxicity.
Conclusions:
- A systems toxicological strategy effectively predicted mechanisms of sunitinib's adverse reactions.
- This approach facilitates the development of rational strategies for managing drug-induced toxicities.
- Identified pathways and countermeasures offer potential for improved cancer therapy tolerability.
More Related Videos
Related Concept Videos
Toxicokinetics: Overview
Drug Toxicity: Dose-Dependent Reactions
Drug toxicity: Idiosyncratic Reactions
Drug Toxicity: Overview
Drug Toxicity: Risk factors
Drug Toxicity: Allergic Reactions

